Recent Updates
Recently added Catalysts

Fixed-Combination Bimatoprost/Brimonidine

Phase 2

Glaucoma | Small molecule | Cardiovascular |AbbVie Inc.|Last Updated: Jan 26, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment112
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01863953A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular HypertensionPHASE2 COMPLETED 112Jun 1, 2013Dec 1, 2013Jan 26, 20151 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change From Baseline in Average Eye Mean Diurnal Intraocular Pressure (IOP)
Baseline, Day 42

IOP is a measurement of the fluid pressure inside the eye. Average eye mean diurnal IOP is the mean of the average eye IOPs (average IOP of the right and left eyes) at hours 0, 2, 4, 8 and 12. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase in IOP (worsening).

Secondary Endpoints
Change From Baseline in Average Eye Mean Diurnal IOP
Baseline, Day 14, Day 28
Average Eye Mean Diurnal IOP
Day 14, Day 28, Day 42
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Fixed-Combination Bimatoprost/BrimonidineEXPERIMENTALOne drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
Bimatoprost Ophthalmic Solution 0.01% and VehicleACTIVE_COMPARATOROne drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
Brimonidine Tartrate Ophthalmic Solution 0.2%ACTIVE_COMPARATOROne drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
Interventions
NameTypeDescription
Fixed-Combination Bimatoprost/BrimonidineDRUGOne drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
Bimatoprost Ophthalmic Solution 0.01%DRUGOne drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.
Vehicle Ophthalmic SolutionDRUGOne drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
Brimonidine Tartrate Ophthalmic Solution 0.2%DRUGOne drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
Unlock Study Design Details
Eligibility Criteria
Age Range40 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Diagnosis of ocular hypertension or glaucoma * Requires intraocular pressure (IOP)-lowering therapy Exclusion Criteria: * Cataract surgery in one eye * Ocular laser or intraocular surgery within 6 months * Refractive surgery in either eye * Anticipated use of contact lenses ...

Countries:United States
Unlock Eligibility Criteria